{
  "version": "2.0",
  "last_updated": "2026-02-04",
  "description": "Master index of biopharma companies with classification metadata",
  "companies": [
    {
      "ticker": "ARGX",
      "name": "argenx SE",
      "development_stage": "commercial_stage",
      "modality": "antibody_biologics",
      "modality_subtype": "mAb",
      "therapeutic_area": "rare_genetic",
      "therapeutic_subtype": "Neurologic",
      "thesis_type": "commercial_compounder",
      "market_cap_mm": 35000,
      "fund_ownership_pct": 2.8,
      "priority": "high",
      "has_data": false,
      "notes": "Vyvgart blockbuster; FcRn leader; multiple indications"
    },
    {
      "ticker": "ARWR",
      "name": "Arrowhead Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 5000,
      "fund_ownership_pct": 0,
      "priority": "high",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "ASND",
      "name": "Ascendis Pharma",
      "development_stage": "commercial_stage",
      "modality": "antibody_biologics",
      "modality_subtype": "Fc-Fusion",
      "therapeutic_area": "rare_metabolic",
      "therapeutic_subtype": "Endocrine",
      "thesis_type": "commercial_compounder",
      "market_cap_mm": 8500,
      "fund_ownership_pct": 3.1,
      "priority": "high",
      "has_data": true,
      "notes": "TransCon platform; Skytrofa approved, YORVIPATH launch"
    },
    {
      "ticker": "CNTA",
      "name": "Centessa Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "Enzyme Inhibitor",
      "therapeutic_area": "cardiometabolic",
      "therapeutic_subtype": "CV",
      "thesis_type": "sum_of_parts",
      "market_cap_mm": 1800,
      "fund_ownership_pct": 3.5,
      "priority": "high",
      "has_data": false,
      "notes": "Lixisenatide in PH; ORX750 in narcolepsy"
    },
    {
      "ticker": "EWTX",
      "name": "Edgewise Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "Enzyme Inhibitor",
      "therapeutic_area": "rare_genetic",
      "therapeutic_subtype": "Muscular",
      "thesis_type": "binary_event",
      "market_cap_mm": 2400,
      "fund_ownership_pct": 4.8,
      "priority": "high",
      "has_data": false,
      "notes": "Sevasemten (EDG-5506) for DMD; muscle-selective myosin inhibitor"
    },
    {
      "ticker": "KYMR",
      "name": "Kymera Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "Degrader/PROTAC",
      "therapeutic_area": "i_and_i_autoimmune",
      "therapeutic_subtype": "Dermatology",
      "thesis_type": "sum_of_parts",
      "market_cap_mm": 2100,
      "fund_ownership_pct": 4.2,
      "priority": "high",
      "has_data": true,
      "notes": "Lead degrader company; KT-621 (STAT6) in Phase 2b AD"
    },
    {
      "ticker": "NUVL",
      "name": "Nuvalent",
      "development_stage": "late_clinical",
      "modality": "small_molecule",
      "modality_subtype": "Kinase Inhibitor",
      "therapeutic_area": "oncology_precision",
      "therapeutic_subtype": "Solid Tumor",
      "thesis_type": "binary_event",
      "market_cap_mm": 6200,
      "fund_ownership_pct": 5.1,
      "priority": "high",
      "has_data": false,
      "notes": "NVL-520 (ROS1) and NVL-655 (ALK) in lung cancer"
    },
    {
      "ticker": "SLNO",
      "name": "Soleno Therapeutics",
      "development_stage": "late_clinical",
      "modality": "small_molecule",
      "modality_subtype": "GPCR Modulator",
      "therapeutic_area": "rare_genetic",
      "therapeutic_subtype": "Metabolic",
      "thesis_type": "ma_target",
      "market_cap_mm": 1400,
      "fund_ownership_pct": 2.2,
      "priority": "high",
      "has_data": false,
      "notes": "Diazoxide choline (DCCR) for Prader-Willi syndrome"
    },
    {
      "ticker": "CDTX",
      "name": "Cidara Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 500,
      "fund_ownership_pct": 0,
      "priority": "med_high",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "ELVN",
      "name": "Enliven Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 500,
      "fund_ownership_pct": 0,
      "priority": "med_high",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "GPCR",
      "name": "Structure Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 1500,
      "fund_ownership_pct": 0,
      "priority": "med_high",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "MLYS",
      "name": "Mineralys Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 2000,
      "fund_ownership_pct": 0,
      "priority": "med_high",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "NAMS",
      "name": "NewAmsterdam Pharma",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 3000,
      "fund_ownership_pct": 0,
      "priority": "med_high",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "OCUL",
      "name": "Ocular Therapeutix",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 1000,
      "fund_ownership_pct": 0,
      "priority": "med_high",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "ORKA",
      "name": "Oruka Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 500,
      "fund_ownership_pct": 0,
      "priority": "med_high",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "SION",
      "name": "Sionna Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 3000,
      "fund_ownership_pct": 0,
      "priority": "med_high",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "TRML",
      "name": "Tourmaline Bio",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 1500,
      "fund_ownership_pct": 0,
      "priority": "med_high",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "ALNY",
      "name": "Alnylam Pharmaceuticals",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 30000,
      "fund_ownership_pct": 0,
      "priority": "medium",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "BCAX",
      "name": "Bicara Therapeutics",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 500,
      "fund_ownership_pct": 0,
      "priority": "medium",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "DNTH",
      "name": "Dianthus Therapeutics",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 1000,
      "fund_ownership_pct": 0,
      "priority": "medium",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "GHRS",
      "name": "GH Research",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 600,
      "fund_ownership_pct": 0,
      "priority": "medium",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "IRON",
      "name": "Disc Medicine",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 1500,
      "fund_ownership_pct": 0,
      "priority": "medium",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "LENZ",
      "name": "Lenz Therapeutics",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 1000,
      "fund_ownership_pct": 0,
      "priority": "medium",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "SEPN",
      "name": "Septerna",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 1000,
      "fund_ownership_pct": 0,
      "priority": "medium",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "SPRY",
      "name": "ARS Pharmaceuticals",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 1000,
      "fund_ownership_pct": 0,
      "priority": "medium",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "TSHA",
      "name": "Taysha Gene Therapies",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 500,
      "fund_ownership_pct": 0,
      "priority": "medium",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "TYRA",
      "name": "Tyra Biosciences",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 600,
      "fund_ownership_pct": 0,
      "priority": "medium",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "ACRV",
      "name": "Acrivon Therapeutics",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 150,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "ARTV",
      "name": "Artiva Biotherapeutics",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 200,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "CLYM",
      "name": "Climb Bio",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 200,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "CTMX",
      "name": "CytomX Therapeutics",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 300,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "ELDN",
      "name": "Eledon Pharmaceuticals",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 100,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "FDMT",
      "name": "4D Molecular Therapeutics",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 400,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "GKOS",
      "name": "Glaukos",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 4000,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "HOWL",
      "name": "Werewolf Therapeutics",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 150,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "INSP",
      "name": "Inspire Medical Systems",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 3000,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "JBIO",
      "name": "Jade Biosciences",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 300,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "LRMR",
      "name": "Larimar Therapeutics",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 150,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "MTSR",
      "name": "Metsera",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 1000,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "NKTX",
      "name": "Nkarta",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 200,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "PEPG",
      "name": "PepGen",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 300,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "PHVS",
      "name": "Pharvaris",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 1000,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "SLDB",
      "name": "Solid Biosciences",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 300,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "SRZN",
      "name": "Surrozen",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 100,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "TNGX",
      "name": "Tango Therapeutics",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 500,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "WGS",
      "name": "GeneDx",
      "development_stage": "early_clinical",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 2000,
      "fund_ownership_pct": 0,
      "priority": "med_low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "REGN",
      "name": "Regeneron Pharmaceuticals",
      "development_stage": "commercial_stage",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 100000,
      "fund_ownership_pct": 0,
      "priority": "low",
      "has_data": false,
      "notes": ""
    },
    {
      "ticker": "VRTX",
      "name": "Vertex Pharmaceuticals",
      "development_stage": "commercial_stage",
      "modality": "small_molecule",
      "modality_subtype": "",
      "therapeutic_area": "other",
      "therapeutic_subtype": "",
      "thesis_type": "binary_event",
      "market_cap_mm": 120000,
      "fund_ownership_pct": 0,
      "priority": "low",
      "has_data": false,
      "notes": ""
    }
  ],
  "stats": {
    "total_companies": 48,
    "with_data": 2,
    "by_priority": {
      "high": 8,
      "med_high": 9,
      "medium": 10,
      "med_low": 19,
      "low": 2
    },
    "by_stage": {
      "commercial_stage": 4,
      "mid_clinical": 13,
      "late_clinical": 2,
      "early_clinical": 29
    }
  }
}